Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Can DBS in early Parkinson’s disease reduce disease progression?

Publish date:: July 8, 2020

Key clinical point: DBS plus standard medical therapy may reduce disease progression and decrease the need for polypharmacy in patients with early Parkinson’s disease.

Major finding: The odds ratio of worse rest tremor at 5 years was 0.21 among patients who received DBS and drug therapy, compared with patients who received drug therapy alone.

Study details: An observational extension of a 2-year pilot study of 30 patients with early-stage Parkinson’s disease.

Disclosures: Medtronic, which manufactures the DBS device that the investigators used, provided part of the study’s funding. The lead researcher’s institution receives money for educational programs and research that he leads.

Citation:

Hacker ML et al. Neurology. 2020 Jun 29. doi: 10.1212/WNL.0000000000009946.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Movement Disorders

Blood biomarker may predict Parkinson’s disease progression,

Can DBS in early Parkinson’s disease reduce disease progression?,

Huntington's disease biomarkers appear 24 years before clinical symptoms,

Nilotinib is safe in moderate and advanced Parkinson’s disease,

GI symptoms in Parkinson’s disease correlate with less microbial diversity,